Carnosine decreased oxidation and glycation products in serum and liver of high‐fat diet and low‐dose streptozotocin‐induced diabetic rats
Summary High‐fat diet (HFD) and low‐dose streptozotocin (STZ)‐treated rats provide useful animal model for type II diabetes mellitus. Oxidative stress and advanced glycation end products (AGEs) play a role in the development of diabetic complications. Carnosine (CAR) has anti‐oxidant and anti‐glycat...
Gespeichert in:
| Veröffentlicht in: | International journal of experimental pathology 2017-10, Vol.98 (5), p.278-288 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 288 |
|---|---|
| container_issue | 5 |
| container_start_page | 278 |
| container_title | International journal of experimental pathology |
| container_volume | 98 |
| creator | Aydın, Abdurrahman Fatih Bingül, İlknur Küçükgergin, Canan Doğan‐Ekici, Işın Doğru Abbasoğlu, Semra Uysal, Müjdat |
| description | Summary
High‐fat diet (HFD) and low‐dose streptozotocin (STZ)‐treated rats provide useful animal model for type II diabetes mellitus. Oxidative stress and advanced glycation end products (AGEs) play a role in the development of diabetic complications. Carnosine (CAR) has anti‐oxidant and anti‐glycating properties. We investigated the effects of CAR on oxidation and glycation products in HFD+STZ rats. Rats were fed with HFD (60% of total calories from fat) for 4 weeks, and then a single dose of STZ (40 mg/kg; i.p.) was applied. Rats with blood glucose levels above 200 mg/dl were fed with HFD until the end of the 12th week. CAR (250 mg/kg body weight; i.p.; five times a week) was administered to the rats for the last four weeks. CAR significantly decreased serum triglyceride (TG) (57.7%), cholesterol (35.6%) levels and hepatic marker enzyme activities of HFD+STZ rats. It significantly reduced serum reactive oxygen species (ROS) (23.7%), AGEs (13.4%) and advanced oxidized protein products (AOPP) (35.9%) and hepatic TG (59%), ROS (26%), malondialdehyde (MDA) (11.5%), protein carbonyl (PC) (19.2%) and AGE (20.2%) levels. Liver steatosis and hepatocyte ballooning were also significantly reduced. However, CAR treatment did not alter serum glucose and blood glycated haemoglobin and hepatic anti‐oxidant enzyme activities/mRNA expressions in HFD+STZ rats. Our results indicate that CAR decreased accumulation of oxidation and glycation products, such as MDA, AGE, AOPP and PC in the serum and liver and ameliorated hepatic dysfunction in HFD+STZ rats. This effect may be related to its anti‐oxidative, anti‐glycating, and anti‐lipogenic potential. |
| doi_str_mv | 10.1111/iep.12252 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5743804</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1980694713</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5092-1501d3254d72a9a29cfc3872b2906cdcb496d1c421eca648dfbee6b7c113d9bd3</originalsourceid><addsrcrecordid>eNp1kc9u1DAQhy0EokvhwAsgS1zgkNZ_4iS-IFWrApUqlQOcLcee7LrK2sF2WpYTj9Bn5EkwTamgEr5Ynvn0zVg_hF5SckTLOXYwHVHGBHuEVpQ3omIN5Y_RikghK9m0_AA9S-mSEMoZbZ-iAyYZEaKTK3Sz1tGH5DxgCyaCTmBx-Oaszi54rL3Fm3FvltcUg51NTth5nCDOu9v-6K4g4jDgrdtsf_64GXTG1kFemuG6lGxIgFOOMOXwPeRgnC9V54utjLNO95CdwVHn9Bw9GfSY4MXdfYi-vD_9vP5YnV98OFufnFdGEMkqKgi1nInatkxLzaQZDO9a1jNJGmNNX8vGUlMzCkY3dWeHHqDpW0Mpt7K3_BC9W7zT3O_AGvA56lFN0e103Kugnfq3491WbcKVEm3NO1IXwZs7QQxfZ0hZ7VwyMI7aQ5iTorLlhBHadAV9_QC9DHP05XuF6kgj65byQr1dKBNDShGG-2UoUb9zViVndZtzYV_9vf09-SfYAhwvwLUbYf9_kzo7_bQofwGbcLjU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1980694713</pqid></control><display><type>article</type><title>Carnosine decreased oxidation and glycation products in serum and liver of high‐fat diet and low‐dose streptozotocin‐induced diabetic rats</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central</source><creator>Aydın, Abdurrahman Fatih ; Bingül, İlknur ; Küçükgergin, Canan ; Doğan‐Ekici, Işın ; Doğru Abbasoğlu, Semra ; Uysal, Müjdat</creator><creatorcontrib>Aydın, Abdurrahman Fatih ; Bingül, İlknur ; Küçükgergin, Canan ; Doğan‐Ekici, Işın ; Doğru Abbasoğlu, Semra ; Uysal, Müjdat</creatorcontrib><description>Summary
High‐fat diet (HFD) and low‐dose streptozotocin (STZ)‐treated rats provide useful animal model for type II diabetes mellitus. Oxidative stress and advanced glycation end products (AGEs) play a role in the development of diabetic complications. Carnosine (CAR) has anti‐oxidant and anti‐glycating properties. We investigated the effects of CAR on oxidation and glycation products in HFD+STZ rats. Rats were fed with HFD (60% of total calories from fat) for 4 weeks, and then a single dose of STZ (40 mg/kg; i.p.) was applied. Rats with blood glucose levels above 200 mg/dl were fed with HFD until the end of the 12th week. CAR (250 mg/kg body weight; i.p.; five times a week) was administered to the rats for the last four weeks. CAR significantly decreased serum triglyceride (TG) (57.7%), cholesterol (35.6%) levels and hepatic marker enzyme activities of HFD+STZ rats. It significantly reduced serum reactive oxygen species (ROS) (23.7%), AGEs (13.4%) and advanced oxidized protein products (AOPP) (35.9%) and hepatic TG (59%), ROS (26%), malondialdehyde (MDA) (11.5%), protein carbonyl (PC) (19.2%) and AGE (20.2%) levels. Liver steatosis and hepatocyte ballooning were also significantly reduced. However, CAR treatment did not alter serum glucose and blood glycated haemoglobin and hepatic anti‐oxidant enzyme activities/mRNA expressions in HFD+STZ rats. Our results indicate that CAR decreased accumulation of oxidation and glycation products, such as MDA, AGE, AOPP and PC in the serum and liver and ameliorated hepatic dysfunction in HFD+STZ rats. This effect may be related to its anti‐oxidative, anti‐glycating, and anti‐lipogenic potential.</description><identifier>ISSN: 0959-9673</identifier><identifier>EISSN: 1365-2613</identifier><identifier>DOI: 10.1111/iep.12252</identifier><identifier>PMID: 29205589</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>advanced glycation end products ; Advanced glycosylation end products ; Animals ; Antioxidants - pharmacology ; Blood ; Blood Glucose - metabolism ; Body weight ; Body Weight - drug effects ; Calories ; Carbonyls ; Carnosine ; Carnosine - pharmacology ; Cholesterol ; Cholesterol - blood ; Complications ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Experimental - etiology ; Diabetes Mellitus, Experimental - metabolism ; Diabetes Mellitus, Experimental - pathology ; Diabetes Mellitus, Type 2 - etiology ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - pathology ; Diet, High-Fat ; Drug Evaluation, Preclinical - methods ; Enzymes ; Fatty liver ; Glucose ; Glycated Hemoglobin A - metabolism ; Glycation End Products, Advanced - metabolism ; Glycosylation ; Hemoglobin ; High fat diet ; Liver ; Liver - metabolism ; Liver - pathology ; Liver diseases ; Male ; Malondialdehyde ; mRNA ; Organ Size - drug effects ; Original ; Oxidation ; Oxidation-Reduction - drug effects ; Oxidative stress ; Oxidative Stress - drug effects ; Rats ; Rats, Wistar ; Reactive oxygen species ; Reactive Oxygen Species - metabolism ; Rodents ; Steatosis ; Streptozocin ; Triglycerides - blood</subject><ispartof>International journal of experimental pathology, 2017-10, Vol.98 (5), p.278-288</ispartof><rights>2017 The Authors. International Journal of Experimental Pathology © 2017 International Journal of Experimental Pathology</rights><rights>2017 The Authors. International Journal of Experimental Pathology © 2017 International Journal of Experimental Pathology.</rights><rights>International Journal of Experimental Pathology © 2017 International Journal of Experimental Pathology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5092-1501d3254d72a9a29cfc3872b2906cdcb496d1c421eca648dfbee6b7c113d9bd3</citedby><cites>FETCH-LOGICAL-c5092-1501d3254d72a9a29cfc3872b2906cdcb496d1c421eca648dfbee6b7c113d9bd3</cites><orcidid>0000-0002-2595-0833</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743804/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743804/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,27901,27902,45550,45551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29205589$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aydın, Abdurrahman Fatih</creatorcontrib><creatorcontrib>Bingül, İlknur</creatorcontrib><creatorcontrib>Küçükgergin, Canan</creatorcontrib><creatorcontrib>Doğan‐Ekici, Işın</creatorcontrib><creatorcontrib>Doğru Abbasoğlu, Semra</creatorcontrib><creatorcontrib>Uysal, Müjdat</creatorcontrib><title>Carnosine decreased oxidation and glycation products in serum and liver of high‐fat diet and low‐dose streptozotocin‐induced diabetic rats</title><title>International journal of experimental pathology</title><addtitle>Int J Exp Pathol</addtitle><description>Summary
High‐fat diet (HFD) and low‐dose streptozotocin (STZ)‐treated rats provide useful animal model for type II diabetes mellitus. Oxidative stress and advanced glycation end products (AGEs) play a role in the development of diabetic complications. Carnosine (CAR) has anti‐oxidant and anti‐glycating properties. We investigated the effects of CAR on oxidation and glycation products in HFD+STZ rats. Rats were fed with HFD (60% of total calories from fat) for 4 weeks, and then a single dose of STZ (40 mg/kg; i.p.) was applied. Rats with blood glucose levels above 200 mg/dl were fed with HFD until the end of the 12th week. CAR (250 mg/kg body weight; i.p.; five times a week) was administered to the rats for the last four weeks. CAR significantly decreased serum triglyceride (TG) (57.7%), cholesterol (35.6%) levels and hepatic marker enzyme activities of HFD+STZ rats. It significantly reduced serum reactive oxygen species (ROS) (23.7%), AGEs (13.4%) and advanced oxidized protein products (AOPP) (35.9%) and hepatic TG (59%), ROS (26%), malondialdehyde (MDA) (11.5%), protein carbonyl (PC) (19.2%) and AGE (20.2%) levels. Liver steatosis and hepatocyte ballooning were also significantly reduced. However, CAR treatment did not alter serum glucose and blood glycated haemoglobin and hepatic anti‐oxidant enzyme activities/mRNA expressions in HFD+STZ rats. Our results indicate that CAR decreased accumulation of oxidation and glycation products, such as MDA, AGE, AOPP and PC in the serum and liver and ameliorated hepatic dysfunction in HFD+STZ rats. This effect may be related to its anti‐oxidative, anti‐glycating, and anti‐lipogenic potential.</description><subject>advanced glycation end products</subject><subject>Advanced glycosylation end products</subject><subject>Animals</subject><subject>Antioxidants - pharmacology</subject><subject>Blood</subject><subject>Blood Glucose - metabolism</subject><subject>Body weight</subject><subject>Body Weight - drug effects</subject><subject>Calories</subject><subject>Carbonyls</subject><subject>Carnosine</subject><subject>Carnosine - pharmacology</subject><subject>Cholesterol</subject><subject>Cholesterol - blood</subject><subject>Complications</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Experimental - etiology</subject><subject>Diabetes Mellitus, Experimental - metabolism</subject><subject>Diabetes Mellitus, Experimental - pathology</subject><subject>Diabetes Mellitus, Type 2 - etiology</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - pathology</subject><subject>Diet, High-Fat</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Enzymes</subject><subject>Fatty liver</subject><subject>Glucose</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Glycation End Products, Advanced - metabolism</subject><subject>Glycosylation</subject><subject>Hemoglobin</subject><subject>High fat diet</subject><subject>Liver</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Malondialdehyde</subject><subject>mRNA</subject><subject>Organ Size - drug effects</subject><subject>Original</subject><subject>Oxidation</subject><subject>Oxidation-Reduction - drug effects</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reactive oxygen species</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Rodents</subject><subject>Steatosis</subject><subject>Streptozocin</subject><subject>Triglycerides - blood</subject><issn>0959-9673</issn><issn>1365-2613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQhy0EokvhwAsgS1zgkNZ_4iS-IFWrApUqlQOcLcee7LrK2sF2WpYTj9Bn5EkwTamgEr5Ynvn0zVg_hF5SckTLOXYwHVHGBHuEVpQ3omIN5Y_RikghK9m0_AA9S-mSEMoZbZ-iAyYZEaKTK3Sz1tGH5DxgCyaCTmBx-Oaszi54rL3Fm3FvltcUg51NTth5nCDOu9v-6K4g4jDgrdtsf_64GXTG1kFemuG6lGxIgFOOMOXwPeRgnC9V54utjLNO95CdwVHn9Bw9GfSY4MXdfYi-vD_9vP5YnV98OFufnFdGEMkqKgi1nInatkxLzaQZDO9a1jNJGmNNX8vGUlMzCkY3dWeHHqDpW0Mpt7K3_BC9W7zT3O_AGvA56lFN0e103Kugnfq3491WbcKVEm3NO1IXwZs7QQxfZ0hZ7VwyMI7aQ5iTorLlhBHadAV9_QC9DHP05XuF6kgj65byQr1dKBNDShGG-2UoUb9zViVndZtzYV_9vf09-SfYAhwvwLUbYf9_kzo7_bQofwGbcLjU</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Aydın, Abdurrahman Fatih</creator><creator>Bingül, İlknur</creator><creator>Küçükgergin, Canan</creator><creator>Doğan‐Ekici, Işın</creator><creator>Doğru Abbasoğlu, Semra</creator><creator>Uysal, Müjdat</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2595-0833</orcidid></search><sort><creationdate>201710</creationdate><title>Carnosine decreased oxidation and glycation products in serum and liver of high‐fat diet and low‐dose streptozotocin‐induced diabetic rats</title><author>Aydın, Abdurrahman Fatih ; Bingül, İlknur ; Küçükgergin, Canan ; Doğan‐Ekici, Işın ; Doğru Abbasoğlu, Semra ; Uysal, Müjdat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5092-1501d3254d72a9a29cfc3872b2906cdcb496d1c421eca648dfbee6b7c113d9bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>advanced glycation end products</topic><topic>Advanced glycosylation end products</topic><topic>Animals</topic><topic>Antioxidants - pharmacology</topic><topic>Blood</topic><topic>Blood Glucose - metabolism</topic><topic>Body weight</topic><topic>Body Weight - drug effects</topic><topic>Calories</topic><topic>Carbonyls</topic><topic>Carnosine</topic><topic>Carnosine - pharmacology</topic><topic>Cholesterol</topic><topic>Cholesterol - blood</topic><topic>Complications</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Experimental - etiology</topic><topic>Diabetes Mellitus, Experimental - metabolism</topic><topic>Diabetes Mellitus, Experimental - pathology</topic><topic>Diabetes Mellitus, Type 2 - etiology</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - pathology</topic><topic>Diet, High-Fat</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Enzymes</topic><topic>Fatty liver</topic><topic>Glucose</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Glycation End Products, Advanced - metabolism</topic><topic>Glycosylation</topic><topic>Hemoglobin</topic><topic>High fat diet</topic><topic>Liver</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Malondialdehyde</topic><topic>mRNA</topic><topic>Organ Size - drug effects</topic><topic>Original</topic><topic>Oxidation</topic><topic>Oxidation-Reduction - drug effects</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reactive oxygen species</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Rodents</topic><topic>Steatosis</topic><topic>Streptozocin</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aydın, Abdurrahman Fatih</creatorcontrib><creatorcontrib>Bingül, İlknur</creatorcontrib><creatorcontrib>Küçükgergin, Canan</creatorcontrib><creatorcontrib>Doğan‐Ekici, Işın</creatorcontrib><creatorcontrib>Doğru Abbasoğlu, Semra</creatorcontrib><creatorcontrib>Uysal, Müjdat</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of experimental pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aydın, Abdurrahman Fatih</au><au>Bingül, İlknur</au><au>Küçükgergin, Canan</au><au>Doğan‐Ekici, Işın</au><au>Doğru Abbasoğlu, Semra</au><au>Uysal, Müjdat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carnosine decreased oxidation and glycation products in serum and liver of high‐fat diet and low‐dose streptozotocin‐induced diabetic rats</atitle><jtitle>International journal of experimental pathology</jtitle><addtitle>Int J Exp Pathol</addtitle><date>2017-10</date><risdate>2017</risdate><volume>98</volume><issue>5</issue><spage>278</spage><epage>288</epage><pages>278-288</pages><issn>0959-9673</issn><eissn>1365-2613</eissn><abstract>Summary
High‐fat diet (HFD) and low‐dose streptozotocin (STZ)‐treated rats provide useful animal model for type II diabetes mellitus. Oxidative stress and advanced glycation end products (AGEs) play a role in the development of diabetic complications. Carnosine (CAR) has anti‐oxidant and anti‐glycating properties. We investigated the effects of CAR on oxidation and glycation products in HFD+STZ rats. Rats were fed with HFD (60% of total calories from fat) for 4 weeks, and then a single dose of STZ (40 mg/kg; i.p.) was applied. Rats with blood glucose levels above 200 mg/dl were fed with HFD until the end of the 12th week. CAR (250 mg/kg body weight; i.p.; five times a week) was administered to the rats for the last four weeks. CAR significantly decreased serum triglyceride (TG) (57.7%), cholesterol (35.6%) levels and hepatic marker enzyme activities of HFD+STZ rats. It significantly reduced serum reactive oxygen species (ROS) (23.7%), AGEs (13.4%) and advanced oxidized protein products (AOPP) (35.9%) and hepatic TG (59%), ROS (26%), malondialdehyde (MDA) (11.5%), protein carbonyl (PC) (19.2%) and AGE (20.2%) levels. Liver steatosis and hepatocyte ballooning were also significantly reduced. However, CAR treatment did not alter serum glucose and blood glycated haemoglobin and hepatic anti‐oxidant enzyme activities/mRNA expressions in HFD+STZ rats. Our results indicate that CAR decreased accumulation of oxidation and glycation products, such as MDA, AGE, AOPP and PC in the serum and liver and ameliorated hepatic dysfunction in HFD+STZ rats. This effect may be related to its anti‐oxidative, anti‐glycating, and anti‐lipogenic potential.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29205589</pmid><doi>10.1111/iep.12252</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2595-0833</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-9673 |
| ispartof | International journal of experimental pathology, 2017-10, Vol.98 (5), p.278-288 |
| issn | 0959-9673 1365-2613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5743804 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; PubMed Central |
| subjects | advanced glycation end products Advanced glycosylation end products Animals Antioxidants - pharmacology Blood Blood Glucose - metabolism Body weight Body Weight - drug effects Calories Carbonyls Carnosine Carnosine - pharmacology Cholesterol Cholesterol - blood Complications Diabetes Diabetes mellitus Diabetes Mellitus, Experimental - etiology Diabetes Mellitus, Experimental - metabolism Diabetes Mellitus, Experimental - pathology Diabetes Mellitus, Type 2 - etiology Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - pathology Diet, High-Fat Drug Evaluation, Preclinical - methods Enzymes Fatty liver Glucose Glycated Hemoglobin A - metabolism Glycation End Products, Advanced - metabolism Glycosylation Hemoglobin High fat diet Liver Liver - metabolism Liver - pathology Liver diseases Male Malondialdehyde mRNA Organ Size - drug effects Original Oxidation Oxidation-Reduction - drug effects Oxidative stress Oxidative Stress - drug effects Rats Rats, Wistar Reactive oxygen species Reactive Oxygen Species - metabolism Rodents Steatosis Streptozocin Triglycerides - blood |
| title | Carnosine decreased oxidation and glycation products in serum and liver of high‐fat diet and low‐dose streptozotocin‐induced diabetic rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A53%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carnosine%20decreased%20oxidation%20and%20glycation%20products%20in%20serum%20and%20liver%20of%20high%E2%80%90fat%20diet%20and%20low%E2%80%90dose%20streptozotocin%E2%80%90induced%20diabetic%20rats&rft.jtitle=International%20journal%20of%20experimental%20pathology&rft.au=Ayd%C4%B1n,%20Abdurrahman%20Fatih&rft.date=2017-10&rft.volume=98&rft.issue=5&rft.spage=278&rft.epage=288&rft.pages=278-288&rft.issn=0959-9673&rft.eissn=1365-2613&rft_id=info:doi/10.1111/iep.12252&rft_dat=%3Cproquest_pubme%3E1980694713%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1980694713&rft_id=info:pmid/29205589&rfr_iscdi=true |